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(Figure 1).
Methods, Intervention, & Analysis: As the storm ap-
proached, interdisciplinary teams discharged many patients
hospital-wide, however the BMTU patients were deemed
unable to discharge. Private HEPA ﬁltered rooms were
blocked on the regular oncology unit as reserve in case the
BMTU became compromised. Nurses followed procedures for
blackout and computer down time; including the printing of
essential information from the electronic medical record
(EMR). Once power and communication systems failed,
nurses and other interdisciplinary team members safely
evacuated patients using med sled evacuation devices and
necessary equipment for monitoring and support down
sixteen ﬂights of dark stairwells to waiting ambulances. To
ensure safe transfer and a hand-off report to the receiving
hospital, nurses accompanied all BMTU patients. Hand-off
communication was also accomplished centrally from the
HICS using the previously printed EMR summaries (Figure 2).
Findings & Interpretation: A total of four patients, including
one autologous transplant patient and patients with
chemotherapy infusing, were transported to a neighboring
hospital without interruption of care. Staff relied on prior
disaster training, expert clinical judgment, and emotional
intelligence to accomplish this unprecedented task.
Discussion & Implications: Disaster training and drills are
vital to developing the skills needed during an emergency.
Nurses, as ﬁrst responders, lead in times of disaster. The ef-
forts of this team demonstrate what can be accomplished
when everyone is well trained and focused on the same goal,
patient safety.502
Does Plerixafor do the trick in mobilising Stem Cells?
Serpil Vieira, Diane Monroe. The London Clinic, London,
United Kingdom
Topic Signiﬁcance & Study Purpose/Background/Rationale:
Plerixafor (MOZOBIL) is an antagonist of alpha-chemokine
receptor CXCR and one of the recent additions to the Hae-
matology discipline; it is used as a stem cell mobiliser. CXCR4
alpha-chemokine receptors are important in hematopoietic
stem cells homing to the bone marrow and in hematopoietic
stem cell quiescence. It is indicated in combination with
Granulocyte Colony Stimulating Factor (GCSF) for Peripheral
Blood Stem Cell (PBSC) collections in the Multiple Myeloma
(MM) and Lymphoma patient groups with a poor mobi-
lisation history.
Methods, Intervention, & Analysis: Method In our organi-
sation, data was collected prospectively. 35 patients (two
patients were included twice as they received Prelixafor on
two separate occasions) received Plerixafor for PBSC collec-
tion between May 2009 and September 2012. Patients met
the criteria prior to treatment, except three patients with low
platelet counts (white Blood Count> 2.5 x 109/L, Absolute
Neutrophil Count > 1.5 x 109/L, Platelet> 85 x 109/L, Serum
Creatinine < 1.5 mg/dL, Aspartate transaminase (AST),
Alanine Transaminase (ALT), Bilirubin < 2 x ULN with no
evidence of Hepatitis B and C. Patient demographic data is
shown in Table 1. Five patients had an underlying docu-
mented medical problem (cortochondritis, asthma, hyper-
tension and glaucoma).
Findings & Interpretation: Result: 25 of the patients were
diagnosed with MM and six with Non-Hodgkin’s Lymphoma
(NHL), two patients had Hodgkin’s Disease, one had Neuro-
blastoma and one Walderstorm’s Macroglobulinameia. All
patients received four consecutive days of GCSF 10 mg/kgprior to Plerixafor. Plerixafor was given 10 hours before the
PBSC collection and GCSF was repeated one hour prior to
PBSC collection on the morning. All patients received 0.24
mg/kg/day of Plerixafor. There were no side effects observed
in these episodes. 26 patients required single dose, 10 pa-
tients required a second dose, and only one patient received
three dose of Plerixafor.
For all cases, the target CD34+ count was 4 x 106 cells/kg
of recipient body weight. Two patients responded extremely
well with a CD34+ count of 21.79 x 106 cells/kg and 15.16
x106 cells/kg achieved. 13 patients achieved the target of 4
X106 cells/kg or above. However 22 patients failed to achieve
to reach target. 16 of these patients had adequate amounts of
CD34 count for an autologous transplant. Four patient failed
to mobilise with CD 34+ <2 X109cells/kg. Only six patient
had > CD 34+ <2 X109cells/kg one of this patient had no
CD34+ at all.
Discussion & Implications: Conclusion Plerixafor was used
at The London Clinic recently with mostly favourable out-
comes. According to this study Plerixafor has improved PBSC
outcomes with some exceptions. Plerixafor has deﬁnitely
made a positive difference in 40% of our patients and 83% had
enough cells for an autologus transplant. However, results
are inconclusive due to small patient numbers. Ongoing
studies with new patient experiences are needed. More than
one dose of Plerixafor may be required for heavily pre-
treated patients who are historically poor mobilisers of PBSC
collections.503
Do we give too much or too little?
Serpil Vieira, Diane Monroe. The London Clinic, London,
United Kingdom
Topic Signiﬁcance & Study Purpose/Background/Rationale:
Introduction Over the last decade, information for cancer
patients has become increasingly more available. The very
nature of cancer requires patients to learn about their disease
in order to copewith the consequences of treatment and to be
involved in decision making processes. It is therefore vital to
provide enough information for patients and their relevant
others. People/patients vary in the amount of information
they require. Evidence suggests that some patients do not
want very much information about their diseases and treat-
ments. This study aims to explore howmuch information our
patient group wants to know and howmuch information our
team provides.
Methods, Intervention, & Analysis: Method A question-
naire was prepared to collect data on howmuch information
was given to patients on three different stages of their
treatment plans. These stages were: on admission, during
their inpatient stay and on discharge. A fourth section was
added, to investigate other information that patient felt
would be beneﬁcial. 112 questionnaires were given between
May 2010 and October 2012, outcome data is shown in Table
I. Stage Information provided on the following topics N, %
On admission
1. Side effects of therapy or chemotherapy 39 (34.8%)




5. Results of diagnostic test 49(43.7%)
6. Follow up, appointments 39(34.8%)
7. Diet 23(20.5%) other 0(0%)
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1. Side effects of therapy or chemotherapy 41(36.6%)
2. Procedures (Bone Marrow Aspiration, Hickman Line
insertion etc) 39(34.8%)
3. Infection Control 48(42.8%)
4. Sexuality 9(8%)
5. Fertility 11(9.8%)
6. Results of diagnostic test 59(52.7%)
7. others, blood tests 7(6.2%)
On discharge
1. Outcome of your treatment 65(58%)
2. Follow up, appointment 102(91%)
3. Medication 108(96.4%)
4. What happens next 88(78.5%)
5. When to call the medical team (Hospital) 94(83.9%)
6. Work life 68(60.7%)
7. Other alternative treatment regimens 8(7.1 %)
Total 112 (100%)
Findings & Interpretation: 112 malignant haematology
patients were admitted to our unit for various reasons Our
audit was evaluated in three different stages. The admission
stage; most of the information provided regarded side effects
of treatment and test results (See Table I). Our audit has
shown that, the admission stage was the lowest in terms of
information providing. It should be kept in mind that the
haematology patient group generally has a long hospital-
isation, the data collection tool was given on discharge.
Therefore, it was interpreted that data might be lost due to
poor recall of the information required. We are now giving
the data collection tool on admission rather than on
discharge in an effort to address this matter. Result showed
that Sexuality (9.8%) and fertility (11.6%) were the least
addressed topics; where as results of diagnostic test (43.7%)
was deemed the most important. On the other hand results
also showed our patient were happy about the information
they were given especially on discharge, as most aspects of
information was covered.
Discussion & Implications: For the haematology patient
group, knowing their diseases and potential outcomes does
help in the difﬁcult decision making process of their treat-
ment. Therefore as healthcare professionals it is our duty of
care to provide the information they need, but how far do we
need to go? This study was aimed at exploring our patient
groups information needs as well as providing a self per-
formance check. Our audit showed that our centre does
perform well in admission and discharge stages; we need to
work on the in patient period. In order to collect the required
data, we have decided to give patients the data collection
tool on admission rather than discharge.504
Can Platelet transfusion be unnecessary?
Serpil Vieira, Diane Monroe. The London Clinic, London,
United Kingdom
Topic Signiﬁcance & Study Purpose/Background/Rationale:
Introduction Blood transfusion continues to be an essential
part of modern practise, but it is not without risk. During the
last decade there has been an increased interest across the
United Kingdom (UK) and Europe in collecting data on the
hazards of transfusion of blood components. Therefore
avoiding unnecessary transfusion is accepted as one way ofreducing the risk, which is associated with blood transfusion.
In our stem cell transplant unit we audited platelet trans-
fusion (PT).
Methods, Intervention, & Analysis: Method The audit was
carried out prospectively and retrospectively. The data was
validated and cross checked retrospectively, all inpatient
episodes were recorded on a monthly basis. The audit was
carried out over a 29 month period from May 2010 until the
end of September 2012. The duration was divided in three
periods in order to compare the outcome with our initial
audit.
Period I: 01/05/10- 31/10/10
Period II: 01/11/10- 30/09/11
Period III: 01/10/11- 30/09/12
Findings & Interpretation: Our unit policy is to keep the
platelet count at circa 10X109/L for uncomplicated inpatients
and at circa 20 x 109/L for complicated patients and out-
patients. We also aimed to keep platelet above 50 x 109/L if
patient is receiving anticoagulant or bleeding for various
reasons. In the comparison of the three periods, there was a
dramatic improvement in terms of reducing the unnecessary
platelet transfusion. As shown on Table 1, in period I 36% of
the transfusion occurred when plt> 31 x 109/L, where as on
period III, this ﬁgure dropped to 13.95. The reasons for un-
usual transfusion were bleeding, prior to invasive procedure
and anticoagulant use. As the ﬁgures are shown there was a
dramatic change in the period II and III compared with
period I regarding unnecessary platelet transfusion. It is also
highlighted the recent change in anticoagulant use due to
new VTE prophylaxis has caused in the numbers of platelet
transfusion when plt > 31X x 109/L. Even though there was
an increase due to VTE policy, the ﬁgures were still lower
than previous periods.
Discussion & Implications: Our organisation recognises the
importance of risk associated in unnecessary blood compo-
nent transfusion. Our audit has shown interesting ﬁgures.
The duration of audit was divided in three different periods
and outcomes compared. Between these three periods there
were dramatic changes as Table II shows. Our ﬁgures drop-
ped rapidly from 45.5% to 16.6% in platelet transfusion when
the platelet count was higher than 31 x109/L. There were
various reasons to transfuse platelets even though the count
was reasonable for the haematology patient group such as:
bleeding, prior to invasive procedure and anticoagulant use.505
Tranfuse or not to Transfuse?
Serpil Vieira, Diane Monroe. The London Clinic, London,
United Kingdom
Topic Signiﬁcance & Study Purpose/Background/Rationale:
Blood transfusion continues to be an essential part of modern
practise but it is not without risk. During the last decade there
has been an increased interest across the United Kingdom
(UK) and Europe for collecting data on the hazards of trans-
fusion of blood components. Therefore avoiding unnecessary
transfusion is accepted as oneway of reducing the risk, which
is associated with blood transfusion. In our stem cell trans-
plant unit we have audited red cell transfusions. Our unit
policy is to keep the haemoglobin level above 8g/dL, this may
change from time to time and depends on the patient’s
clinical condition.
Methods, Intervention, & Analysis: The audit was carried
out prospectively and retrospectively. The datawas validated
and cross checked retrospectively, all inpatient data was
recorded on amonthly basis. The audit was carried out over a
period of 29 months from May 2010 until end of September
